OBJECTIVE: We wished to assess, in heavily treatment-experienced patients, the prevalence of and baseline characteristics associated with HIV-1 coreceptor use and their relationship to responses to enfuvirtide treatment. METHODS: Samples were obtained from participants in phase 3 studies of enfuvirtide. Multiple logistic regression and analysis of covariance were performed on data for baseline coreceptor use, virological and immunological response, and changes in coreceptor use during treatment. RESULTS: Baseline envelopes were phenotyped for 724 patients; 50% harbored R5 strains, 48% harbored dual/mixed (D/M) strains, and 2% harbored X4 strains. D/M strains were associated with significantly lower CD4(+) cell counts but comparable viral loads, compared with R5 strains (P=.0005). Virological and immunological responses to enfuvirtide-based treatment showed no correlation with baseline coreceptor use. Changes in virus tropism from D/M to R5 strains during treatment were common, particularly in patients who received enfuvirtide (27%, vs. 14% who received no enfuvirtide; P<.05). CONCLUSION: At baseline, D/M strains were associated with lower CD4(+) cell counts but similar viral loads, compared with R5 strains, and were common across CD4(+) cell count strata. The comparable virological and immunological responses and bias toward shifts from D/M to R5 strains in patients who received enfuvirtide support its use in triple-class treatment-experienced patients and its study as a therapeutic partner for coreceptor-binding inhibitors.
RCT Entities:
OBJECTIVE: We wished to assess, in heavily treatment-experienced patients, the prevalence of and baseline characteristics associated with HIV-1 coreceptor use and their relationship to responses to enfuvirtide treatment. METHODS: Samples were obtained from participants in phase 3 studies of enfuvirtide. Multiple logistic regression and analysis of covariance were performed on data for baseline coreceptor use, virological and immunological response, and changes in coreceptor use during treatment. RESULTS: Baseline envelopes were phenotyped for 724 patients; 50% harbored R5 strains, 48% harbored dual/mixed (D/M) strains, and 2% harbored X4 strains. D/M strains were associated with significantly lower CD4(+) cell counts but comparable viral loads, compared with R5 strains (P=.0005). Virological and immunological responses to enfuvirtide-based treatment showed no correlation with baseline coreceptor use. Changes in virus tropism from D/M to R5 strains during treatment were common, particularly in patients who received enfuvirtide (27%, vs. 14% who received no enfuvirtide; P<.05). CONCLUSION: At baseline, D/M strains were associated with lower CD4(+) cell counts but similar viral loads, compared with R5 strains, and were common across CD4(+) cell count strata. The comparable virological and immunological responses and bias toward shifts from D/M to R5 strains in patients who received enfuvirtide support its use in triple-class treatment-experienced patients and its study as a therapeutic partner for coreceptor-binding inhibitors.
Authors: Jessica D Church; Wei Huang; Anthony Mwatha; Philippa Musoke; J Brooks Jackson; Danstan Bagenda; Saad B Omer; Deborah Donnell; Clemensia Nakabiito; Chineta Eure; Laura A Guay; Allan Taylor; Paul M Bakaki; Flavia Matovu; Michelle McConnell; Mary Glenn Fowler; Susan H Eshleman Journal: Curr HIV Res Date: 2010-10 Impact factor: 1.581
Authors: Jinyun Yuan; Jianbin Wang; Karen Crain; Colleen Fearns; Kenneth A Kim; Kevin L Hua; Philip D Gregory; Michael C Holmes; Bruce E Torbett Journal: Mol Ther Date: 2012-01-24 Impact factor: 11.454
Authors: James F Demarest; Heather Amrine-Madsen; David M Irlbeck; Kathryn M Kitrinos Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191
Authors: Wei Huang; Jonathan Toma; Eric Stawiski; Signe Fransen; Terri Wrin; Neil Parkin; Jeannette M Whitcomb; Eoin Coakley; Frederick M Hecht; Steven G Deeks; Rajesh T Gandhi; Susan H Eshleman; Christos J Petropoulos Journal: AIDS Res Hum Retroviruses Date: 2009-08 Impact factor: 2.205